Anabel is a Reporter, working across the six Citeline publications. She is a recent graduate from the University of Exeter and holds a BA English degree. Since graduating, Anabel has also completed an editorial internship with the In Vivo team. Before joining Norstella she spent the past year as Editor-in-Chief of her university’s student paper, Exeposé, managing an editorial team to produce a 32-page paper on a fortnightly basis.
Latest from Anabel Costa-Ferreira
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
Richard Lowenthal, co-founder and CEO of ARS Pharmaceuticals, highlights the crucial unmet need for needle-free devices to treat type 1 allergic reactions, given challenges associated with current epinephrine injectors. Hear what’s next for the Neffy intranasal spray and ARS Pharmaceuticals.
Richard Lowenthal, co-founder, and CEO of ARS Pharma, highlights the crucial unmet need for needle-free injections. Challenging issues posed by current epinephrine injectors, In Vivo questions the current and future progression of Neffy.
Patrick Alexandre, Crossject CEO, discusses crucial developments happening for Zeneo, a needle-free injector, functioning intramuscularly to administer medication in a tenth of a second.
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
Patrick Alexandre, Crossject CEO, discusses crucial developments happening for Zeneo, a needle-free injector, functioning intramuscularly to administer medication in a tenth of a second